Eric Lawitz, MD, explains how pharmacists can raise liver risk with patients with obesity and why a FIB-4 score from routine blood work is a good first step.
|Videos|November 9, 2014
Reaction to Next-Generation Pharmacistâ„¢ Lifetime Achievement Award Selection
Michel Disco, BSPharm, RPh, MBA, describes how she reacted to being selected as a Lifetime Achievement award finalist.
Advertisement
Michel Disco, BSPharm, RPh, MBA, describes how she reacted to being selected as a Lifetime Achievement award finalist.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
SubscribeAdvertisement
Related to this article
Pharmacogenomic-guided prescribing uses genetic data to protect patients from dangerous toxicities and get them the right drug at the right dose from the start.
As accessible health care providers, pharmacists can raise awareness about the proper use of OTC blood glucose meters and continuous glucose monitoring devices.
The first AHA endocarditis update in 11 years expands outpatient options, with a bigger role for pharmacists.
Growing evidence points to gallstones and cholecystitis as an underrecognized risk of GLP-1 RA therapy—pharmacists are well positioned to catch it early.
A suspected plague death in Russia has renewed attention on the rare infection. Here's how to spot pneumonic plague, and which antibiotics the CDC recommends.
A meta-analysis of 27 trials found 15% lower cardiovascular (CV) event risk per 10-mm Hg SBP reduction, with eGFR declines but no rise in kidney failure.
As earning years peak, so do spending and responsibility—here’s where midcareer pharmacists should focus their financial decision-making.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Rising Gallbladder Complications With GLP-1 Receptor Agonists Call for Closer Pharmacist Monitoring
2
The Value of Self-Monitoring Blood Glucose Tools in Preventing and Reducing Prediabetes and Diabetes-Related Complications
3
What Different Communities Taught Me About Patient Care
4
Patients Report Early, Sustained Functional Gains With First-Line Zongertinib in HER2-Mutant NSCLC
5